Table 5.
Effect of chrysin and BM-MSCs on serum IL-1β, TNF-α, and IL-13 levels in NA/STZ-induced diabetic rats.
| Groups | IL-1β (pg/mL) |
% Change |
TNF-α (pg/mL) |
% Change |
IL-13 (pg/mL) |
% Change |
|---|---|---|---|---|---|---|
| Normal | 15.23 ± 0.82 a | 42.7 ± 1.45 a | 116.30 ± 3.01 c | |||
| Diabetic control | 91.43 ± 4.55 d | 500.33 | 138.3 ± 7.71 d | 223.89 | 55.13 ± 6.35 a | −52.60 |
| Diabetic treated with chrysin | 31.90 ± 2.75 b | −65.11 | 65.07 ± 1.85 b | −52.95 | 97.13 ± 1.42 b | 76.18 |
| Diabetic treated with BM-MSCs | 39.47 ± 5.58 b,c | −56.83 | 94.5 ± 2.41 c | −31.67 | 95.67 ± 3.49 b | 73.54 |
| Diabetic treated with chrysin and BM-MSCs | 49.07 ± 2.56 c | −46.33 | 44.1 ± 2.08 a | −68.11 | 93.03 ± 6.36 b | 68.75 |
| F-probability | p < 0.001 | p < 0.001 | p < 0.001 | |||
Data are expressed as mean ± SE. Six samples from each group were detected. Means (with various superscript symbols: a, b, c, and d) for each parameter differ significantly at p < 0.05. Percentage changes were calculated by comparing the diabetic control with normal and diabetic treated groups with diabetic control. % change = [(Final − Initial)/Initial] × 100.